Boardroom Alpha
10-K primary document
UNCY · Annual Report (Form 10-K) · Filed March 30, 2026

Unicycive Therapeutics Inc10-K exhibit

ea028198201ex4-4.htm

Exhibit 4.4

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

As of December 31, 2025, Unicycive Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share (“Common Stock”).

 

Unless the context otherwise requires, all references to “we”, “us”, the “Company”, or “Unicycive” in this Exhibit 4.4 refer to Unicycive Therapeutics, Inc.

 

DESCRIPTION OF CAPITAL STOCK

 

The following description of our securities is intended as a summary only and is qualified in its entirety by reference to our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the annual report on Form 10-K of which this Exhibit 4.4 is a part.

 

Authorized Capitalization

 

Our authorized capital stock consists of 400,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”) in one or more series, of which 21,400 shares have been designated as Series A-2 Prime Convertible Preferred Stock, 25,900 shares have been designated as Series A-2 Prime Convertible Preferred Stock 25,700 shares have been designated as Series A-2 Prime Convertible Preferred Stock 51,600 shares have been designated as Series A-2 Prime Convertible Preferred Stock, 50,000 shares have been designated as Series B-1 Convertible Preferred Stock and 50,000 shares have been designated as Series B-2 Convertible Preferred Stock. As of March 30, 2026, we had outstanding 25,237,782 shares of our Common Stock, 2,265 shares of Series A-2 Prime Convertible Preferred Stock, 0 shares of Series A-3 Convertible Preferred Stock 0 shares of Series A-4 Convertible Preferred Stock, 0 shares of Series A-5 Convertible Preferred Stock, 0 shares of Series B-1 Convertible Preferred Stock and 0 shares of Series B-2 Convertible Preferred Stock.

 

Transfer Agent and Registrar. The transfer agent for our Common Stock is Pacific Stock Transfer Company.

 

Listing. Our Common Stock is traded on the Nasdaq Capital Market under the symbol “UNCY.”

 

Common Stock

 

The holders of our common stock are entitled to one vote per share. Our amended and restated certificate of incorporation, as amended, does not provide for cumulative voting. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of our assets which are legally available; however, the current policy of our board of directors is to retain earnings, if any, for operations and growth. Upon our liquidation, dissolution or winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of our board of directors and issued in the future.

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer